BETHESDA, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and …
Results Include Safety, Tolerability, Pharmacokinetics, and Target Engagement GT-02287, in Development for GBA1 Parkinson’s Disease, on Track to Initiate Phase 1b Trial in Patients in …
Topline Results From MAD Phase 1 Study of GT-02287 on Track for August 2024 With Full Presentation at Upcoming Medical Conferences in Early Q4 2024 …
BETHESDA, Md. , Aug. 01, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery …
GT-02287 Well Tolerated With No Serious Adverse Events or Other Safety Signals Reported Additional Topline Data To Be Presented Mid-August GT-02287 on Track To Initiate …
BETHESDA, Md., June 28, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and …
Parkinson’s News Today
BioWorld
Clinical Trials Arena
Fierce Biotech
Neurology Live
PharmaVoice
Gain Therapeutics recently participated in BTIG’s Virtual Biotechnology Conference 2024. We look forward to our continued collaboration and growing knowledge in the biotechnology industry. This …
Business and Corporate Update Call with interim-CEO Gene Mack Date: 8:30am ET, July 1, 2024 Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=EnkGqV2d
H.C. Wainwright Fireside Chat with Gene Mack – 5th Annual Neuro Perspectives Virtual Conference Date: June 27, 2024 Webcast: https://journey.ct.events/view/b9a0531d-bb19-4f33-8566-8e2002792bfb
Public Ventures Discovery Day with Eric Richman Date: March 19, 2024
Gain Therapeutics’ 2024 R&D update with KOL and Analyst Insight Date: Februrary 22, 2023 Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=ISgbES38
FORCE Family Office Webinar/Zacks Small Cap Research Webinar Date: December 5, 2023 Webcast: